1World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation [ R]. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland:World Health Organization. 1999.
2Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta - cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high - risk Hispanic women[J]. Diabetes, 2002,51:2 796.
3Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence [ J ] . Drugs, 2003, 63:1 373.
4Stumvoll M, Fritsche A, Stefan N, et al. Evidence against a rate - limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and betacell dysfunction[J] . J Clin Endocrinol Metab, 2001, 86 (3) :1235.
5O'Meara NM, Studs J, Van Cauter E, et al. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non - insulin - dependent diabetes mellitus[ J]. J Chin Invest, 1993,92:262.
6Yki - Jarvinen H. Glucose toxicity[J]. Endocr Rev ,1992,13:415.
7Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26:Sulphonylurea failure in non - insulin - dependent diabetic patients over six years[J]. Diabet Med, 1998, 15: 297.
8Shimabukuro M, Zhou YT, Levi M, et al. Fatty acidinduced beta cell apoptosis:A link between obesity and diabetes[J]. Proc Natl Acad Sci USA, 1998, 95: 2498.
9Buchanan TA. Pancreatic B- cell defects in gestational diabetes: Implications for the pathogenesis and prevention of type 2 diabetes[ J]. J Chin Endocrinol Metab, 2001,86:989.
10Atkinson MA, Eisenbarth GS. Type I diabetes: new perspectives on disease pathogenesis and treatment[ J]. Lancet,2001,358(9 277) :221.
2[1]Carlsson A, Sundkvist G, Groop L, et al. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab,2000,85:76-80.
3[2]Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol, 2001, 169:453-459.
4[4]Johansson BL, Brog K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med, 2000, 17:181-189.
5[5]Di Mario U, Dotta F. Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabete Metab Rev, 1993.245-249.
6[6]Kobayashi T, Nakanishi K, Murase T , et al. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes, 1996,45:622-626.
7[7]Kobayashi T, Maruyama T, Shimada A, et al. Insulin intervention to preserve β cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann NY Acad Sci, 2002, 958:117-130.
8[8]Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev,2002,18:114-117.
